SCHEMBL4291622

SCHEMBL4291622

C=C(C(=O)NC(Cc1ccccc1)C(=O)NCC(=O)NCC(=O)O)c1ccco1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 2/20 0.51
ALDH1A1 P00352 5/20 0.47
TSHR P16473 1/20 0.47
MME P08473 5/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ACE P12821 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPT P10636 1/20 0.43
ECE1 P42892 1/20 0.43
BLM P54132 1/20 0.43
NPEPPS P55786 1/20 0.43
CTSS P25774 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6688986 0.96 CTSL (0.55) CTSLALDH1A1TSHRMMECYP1A2
SCHEMBL265813 0.86 CTSL (0.67) CTSLALDH1A1TSHRMMECYP1A2
SCHEMBL1958029 0.81 MME (0.50) CTSLALDH1A1MMECYP1A2CYP3A4
SCHEMBL6664470 0.80 CTSL (0.46) CTSLALDH1A1TSHRMMEACE
SCHEMBL1957422 0.78 ALDH1A1 (0.52) CTSLALDH1A1TSHRMEN1KMT2A
SCHEMBL1955086 0.78 ALDH1A1 (0.52) CTSLALDH1A1TSHRMEN1KMT2A
SCHEMBL27642499 0.78 ALDH1A1 (0.52) CTSLALDH1A1TSHRMEN1KMT2A
SCHEMBL25218054 0.77 MME (0.48) CTSLALDH1A1MMEACEMEN1
SCHEMBL6036874 0.77 SMN1; SMN2 (0.46) ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL29385523 0.77 CTSL (0.51) CTSLALDH1A1MMEACEMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258387-A1 BIOACTIVE WHEY PROTEIN HYDROLYSATE SCHLOTHAUER RALF-CHRISTIAN 2009-10-15 US disclosed
US-20080292750-A1 Method of Preparing a Food Ingredient and Food Product Having Angiotensin-I-Converting Enzyme Inhibiting Properties and Products Thus Obtained CAMOINA NEDERLAND HOLDING B.V. (NL) 2008-11-27 US disclosed
US-20080032915-A1 Cysteine Rich Peptides for Improving Thiol Homeostasis CAMPINA NEDERLAND HOLDING B.V. (NL) 2008-02-07 US disclosed
EP-1727440-A1 METHOD OF PREPARING A FOOD INGREDIENT AND FOOD PRODUCT HAVING ANGIOTENSIN-I-CONVERTING ENZYME INHIBITING PROPERTIES AND PRODUCTS THUS OBTAINED Campina Nederland Holding B.V. (NL) 2006-12-06 EP disclosed
EP-1715881-A1 CYSTEINE RICH PEPTIDES FOR IMPROVING THIOL HOMEOSTASIS Campina Nederland Holding B.V. (NL) 2006-11-02 EP disclosed
CN-1693878-A Method and kit for scaling investigating angiotensin aminopherase ZHEJIANG YAKE PHARMACEUTICAL C (CN) 2005-11-09 CN disclosed
WO-2005096847-A1 METHOD OF PREPARING A FOOD INGREDIENT AND FOOD PRODUCT HAVING ANGIOTENSIN-I-CONVERTING ENZYME INHIBITING PROPERTIES AND PRODUCTS THUS OBTAINED CAMPINA NEDERLAND HOLDING B.V. (NL) 2005-10-20 WO disclosed
WO-2005077400-A1 CYSTEINE RICH PEPTIDES FOR IMPROVING THIOL HOMEOSTASIS CAMPINA NEDERLAND HOLDING B.V. (NL) 2005-08-25 WO disclosed
US-20050164340-A1 Bioactive whey protein hydrolysate SCHLOTHAUER RALF-CHRISTIAN (NZ) 2005-07-28 US disclosed
US-6919314-B1 Bioactive whey protein hydrolysate NEW ZEALAND DAIRY BOARD (NZ) 2005-07-19 US disclosed
WO-1997024342-A1 THIOL DERIVATIVES WITH METALLOPEPTIDASE INHIBITORY ACTIVITY ZAMBON GROUP S.P.A. (IT) 1997-07-10 WO disclosed
WO-1997019102-A1 PHOSPHONIC ACID DERIVATIVES WITH METALLOPEPTIDASE INHIBITORY ACTIVITY ZAMBON GROUP S.P.A. (IT) 1997-05-29 WO disclosed
WO-1997000261-A1 PHOSPHINIC ACID DERIVATIVES WITH METALLOPEPTIDASE INHIBITORY ACTIVITY ZAMBON GROUP S.P.A. (IT) 1997-01-03 WO disclosed
WO-1994023730-A1 METHOD OF TREATING HEPATITIS B INFECTION KREMERS-URBAN COMPANY (US) 1994-10-27 WO disclosed
US-5334395-A Using a polypeptide KREMERS-URBAN COMPANY (US) 1994-08-02 US disclosed
US-5316775-A Mammalian liver extract KREMERS-URBAN COMPANY (US) 1994-05-31 US disclosed
WO-1994004170-A1 METHOD OF TREATING EPSTEIN-BARR VIRUS INFECTION KREMERS-URBAN COMPANY (US) 1994-03-03 WO disclosed
US-5284664-A Administering mammalian liver extract KREMERS-URBAN COMPANY (US) 1994-02-08 US disclosed
EP-0554887-A1 The use of mammalian liver extract for the manufacture of a medicament to treat presenile or senile dementia KREMERS- URBAN CO. (US) 1993-08-11 EP disclosed
EP-0537722-A2 Porcane liver polypeptides for treating viral infections KREMERS- URBAN CO. (US) 1993-04-21 EP disclosed